Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Study of RXDX-106, an Oral Immunomodulatory TYRO3, AXL, and MER (TAM) Tyrosine Kinase Inhibitor, in Patients With Locally Advanced or Metastatic Solid Tumors

Trial Profile

A Study of RXDX-106, an Oral Immunomodulatory TYRO3, AXL, and MER (TAM) Tyrosine Kinase Inhibitor, in Patients With Locally Advanced or Metastatic Solid Tumors

Discontinued
Phase of Trial: Phase 0

Latest Information Update: 25 Sep 2018

At a glance

  • Drugs RXDX-106 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; First in man
  • Acronyms TITAN
  • Sponsors Ignyta
  • Most Recent Events

    • 13 Sep 2018 Status changed from not yet recruiting to discontinued.
    • 02 Mar 2018 Status changed from planning to not yet recruiting.
    • 03 Jan 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top